Acurx Pharmaceuticals (ACXP) Secures New US Patent for DNA Polymerase IIIC Inhibitors

Acurx Pharmaceuticals Inc. (NASDAQ:ACXP) is one of the best up and coming penny stocks to buy. On February 2, Acurx Pharmaceuticals announced that the United States Patent and Trademark Office granted a new patent, US 12,534,470, covering its DNA Polymerase IIIC inhibitors. This patent includes compositions-of-matter, methods of use, and pharmaceutical compositions, reinforcing the company’s intellectual property for its ACX-375C program.

To date, Acurx Pharmaceuticals Inc. (NASDAQ:ACXP) has secured four US patents alongside international grants in Israel, Japan, India, and Australia, with further country-level applications currently under review. Executive Chairman Robert J. DeLuccia stated that this patent extends protection for the company’s AI-supported drug discovery platform, which aims to transform the treatment of life-threatening infections.

Recent preclinical data suggests that microbiome selectivity may be a class effect of these novel compounds when compared to antibiotics like linezolid. While the lead inhibitor, ibezapolstat, is Phase 3-ready for treating C. difficile, these newer preclinical compounds show potential for systemic absorption via oral and parenteral administration. The company’s pipeline targets various serious conditions, including MRSA, community-acquired bacterial pneumonia, bacteremia, and inhalational anthrax. Acurx focuses on developing a new class of small-molecule antibiotics that inhibit the Gram-positive-specific enzyme DNA polymerase IIIC to cause bacterial cell death.

Acurx Pharmaceuticals Inc. (NASDAQ:ACXP) is a clinical-stage biopharmaceutical company that develops antibiotics to treat bacterial infections in the US. The company’s lead antibiotic candidate is ibezapolstat, which targets the polymerase IIIC enzyme.

While we acknowledge the potential of ACXP as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. Follow Insider Monkey on Google News.